FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2550247846> ?p ?o ?g. }

• W2550247846 abstract "Abstract Abstract 4948 Objective To investigate the efficacy and safety of PAD (bortezomib, doxorubicin and dexamethasone) combination therapy for Chinese relapsed or refractory multiple myeloma (MM). Methods 31 patients with relapsed or refractory MM received two to eight 21-days cycles of PAD: comprising an intravenous bolus of bortezomib 1.3 mg/m2 (P1,N=13) or 1.0 mg/m2 (P2,N=18) on days 1, 4, 8, and 11, doxorubicin 10mg per day on days 1 to 4, along with dexamethasone 40mg on days 1-4. Response to PAD was evaluated according to International Myeloma Working Group Criteria (IMWG 2006), toxicity was graded according to NCI CTCAE v3.0. Results 25 patients (80.6%) achieved at least a partial response (PR), including complete response (CR) in 9 patients (29%), very good partial response (VGPR) in 7 patients (22.6%), PR in 9 patients (29%) and stable disease (SD) in 4 patients(12.9%), progression of disease (PD) in 2 patients (6.5%); median time to progression was 9.2 months, the median courses to achieve at least PR was 1.6(1-3) cycles, all of 7 patients with extramedullary plasmacytoma achieved at least PR after the first cycle of PAD, extramedullary plasmacytoma disappeared with 1-2 cycles of PAD. The efficacy was independent of traditional prognostic factors such asβ2-MG, Albumin,LDH and Hemoglobin which have previously influenced response to traditional chemotherapy. 1.5 year OS (Overall survival)of CR+VGPR group and PR group were 87.5% vs 46.7% (P=0.09). ≥PR response rate (CR +VGPR +PR) of P1AD and P2AD were 84.6% VS 77.8% (P= 0.501), CR+VGPR rate of P1AD and P2AD were 53.8% vs 50.0% (P=0.561 ). 1 year PFS(Progession-free survival) of P1AD and P2AD were 61.2% vs 55.6%(P=0.638), there were not difference between P1AD and P2AD in response rate(P= 0.501) and 1 year OS (P=0.872). Adverse events included thrombocytopenia in 15 patients ( 48.4% ), leukopenia in 8 patients(25.8%), peripheral neuropathy in 6 patients (19.4% ), varicella herpes zoster in 7 patients (22.6%), fatigue in 11 patients (35.5%) and diarrhea in 5 patients (16.1%), Thrombocytopenia and peripheral neuropathy of P1AD and P2AD were 46.2% vs 11.1%( P=0.037)and 53.8% vs 11.1%(P= 0.014).Common adverse reactions could be controlled with routine supportive treatmemt, one patient (3.2% ) died from respiratory failure during his fifth P1>AD. Conclusions PAD should be considered an appropriate treatment for Chinese relapsed or refractory MM, especially for MM with extramedullary plasmacytoma, its efficacy were independent of traditional prognosis factors, bortezomib dose reduction may reduce toxicities of PAD while retaining the efficacy. Disclosures No relevant conflicts of interest to declare." @default.
• W2550247846 created "2016-11-30" @default.
• W2550247846 creator A5051245759 @default.
• W2550247846 creator A5055577592 @default.
• W2550247846 creator A5065739638 @default.
• W2550247846 creator A5069694896 @default.
• W2550247846 date "2009-11-20" @default.
• W2550247846 modified "2023-10-01" @default.
• W2550247846 title "Bortezomib, Doxorubicin and Dexamethasone (PAD) Combination Therapy for Chinese Relapsed or Refractory Multiple Myeloma." @default.
• W2550247846 doi "https://doi.org/10.1182/blood.v114.22.4948.4948" @default.
• W2550247846 hasPublicationYear "2009" @default.
• W2550247846 type Work @default.
• W2550247846 sameAs 2550247846 @default.
• W2550247846 citedByCount "0" @default.
• W2550247846 crossrefType "journal-article" @default.
• W2550247846 hasAuthorship W2550247846A5051245759 @default.
• W2550247846 hasAuthorship W2550247846A5055577592 @default.
• W2550247846 hasAuthorship W2550247846A5065739638 @default.
• W2550247846 hasAuthorship W2550247846A5069694896 @default.
• W2550247846 hasConcept C121332964 @default.
• W2550247846 hasConcept C126322002 @default.
• W2550247846 hasConcept C126894567 @default.
• W2550247846 hasConcept C141071460 @default.
• W2550247846 hasConcept C142424586 @default.
• W2550247846 hasConcept C2776364478 @default.
• W2550247846 hasConcept C2776694085 @default.
• W2550247846 hasConcept C2777478702 @default.
• W2550247846 hasConcept C2778822529 @default.
• W2550247846 hasConcept C2780401358 @default.
• W2550247846 hasConcept C2781303535 @default.
• W2550247846 hasConcept C71924100 @default.
• W2550247846 hasConcept C87355193 @default.
• W2550247846 hasConcept C90924648 @default.
• W2550247846 hasConceptScore W2550247846C121332964 @default.
• W2550247846 hasConceptScore W2550247846C126322002 @default.
• W2550247846 hasConceptScore W2550247846C126894567 @default.
• W2550247846 hasConceptScore W2550247846C141071460 @default.
• W2550247846 hasConceptScore W2550247846C142424586 @default.
• W2550247846 hasConceptScore W2550247846C2776364478 @default.
• W2550247846 hasConceptScore W2550247846C2776694085 @default.
• W2550247846 hasConceptScore W2550247846C2777478702 @default.
• W2550247846 hasConceptScore W2550247846C2778822529 @default.
• W2550247846 hasConceptScore W2550247846C2780401358 @default.
• W2550247846 hasConceptScore W2550247846C2781303535 @default.
• W2550247846 hasConceptScore W2550247846C71924100 @default.
• W2550247846 hasConceptScore W2550247846C87355193 @default.
• W2550247846 hasConceptScore W2550247846C90924648 @default.
• W2550247846 hasLocation W25502478461 @default.
• W2550247846 hasOpenAccess W2550247846 @default.
• W2550247846 hasPrimaryLocation W25502478461 @default.
• W2550247846 hasRelatedWork W14747713 @default.
• W2550247846 hasRelatedWork W2068579037 @default.
• W2550247846 hasRelatedWork W2142368474 @default.
• W2550247846 hasRelatedWork W2390144486 @default.
• W2550247846 hasRelatedWork W2521743538 @default.
• W2550247846 hasRelatedWork W2536888824 @default.
• W2550247846 hasRelatedWork W2549246779 @default.
• W2550247846 hasRelatedWork W2552255570 @default.
• W2550247846 hasRelatedWork W2570467653 @default.
• W2550247846 hasRelatedWork W2573079206 @default.
• W2550247846 hasRelatedWork W2581822990 @default.
• W2550247846 hasRelatedWork W2584298559 @default.
• W2550247846 hasRelatedWork W2586553979 @default.
• W2550247846 hasRelatedWork W2588275579 @default.
• W2550247846 hasRelatedWork W2588907662 @default.
• W2550247846 hasRelatedWork W2588946684 @default.
• W2550247846 hasRelatedWork W2601730135 @default.
• W2550247846 hasRelatedWork W2981076752 @default.
• W2550247846 hasRelatedWork W2982715530 @default.
• W2550247846 hasRelatedWork W3031409397 @default.
• W2550247846 isParatext "false" @default.
• W2550247846 isRetracted "false" @default.
• W2550247846 magId "2550247846" @default.
• W2550247846 workType "article" @default.